Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.3 to v3.5.4. This indicates a minor patch to the page.
    Difference
    0.1%
    Check dated 2026-05-18T03:53:24.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    This updates the ClinicalTrials.gov page’s visible revision/version label from v3.5.2 to v3.5.3 without changing any underlying study details.
    Difference
    0.1%
    Check dated 2026-04-26T15:25:13.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-19T13:40:14.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0. No visible changes to study content or page functionality.
    Difference
    0.1%
    Check dated 2026-03-21T17:37:17.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-07T08:41:42.000Z thumbnail image
  9. Check
    108 days ago
    Change Detected
    Summary
    The footer revision tag was updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T17:45:10.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.